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Nitric oxideTryptamine is an endogenous and dietary indoleamine-based trace amine implicated in cardiovascular patholo-
gies, including hypertension, migraine and myocardial infarction. This study aimed at identifying the signalling
pathways for the vasoconstrictor response to tryptamine in rat isolated perfused mesenteric arterial beds and
co-released vasodilator modulators of tryptamine-mediated vasoconstriction. Tryptamine caused concentration-
dependent vasoconstriction of the mesenteric bed, measured as increases in perfusion pressure. These were
inhibited by the 5-HT2A receptor antagonist, ritanserin, indicating mediation via 5-HT2A receptors. The response
was inhibited by the phospholipase C (PLC) and phospholipase A2 (iPLA2) inhibitors, U-73122 and PACOCF3,
suggesting involvement of phospholipase pathways. Activation of these pathways by tryptamine releases cyclo-
oxygenase (COX) products since indomethacin (non-selective inhibitor of COX-1/2) and nimesulide (selective
COX-2 inhibitor) reduced the vasoconstriction. The most likely COX vasoconstrictor product was prostaglandin
PGE2 since the responses to tryptamine were reduced by AH-6809, a non-selective EP1 receptor antagonist.
Involvement of the Rho-kinase pathway in the tryptamine-evoked vasoconstriction was also indicated by its re-
duction by the Rho-kinase inhibitors, Y-27,632 and fasudil. The tryptamine vasoconstriction is modulated by the
co-released endothelial vasodilator, nitric oxide. Thus, circulating tryptamine can regulate mesenteric blood ﬂow
through a cascade of signalling pathways secondary to stimulation of 5-HT2A receptors.
© 2012 Elsevier Inc. Open access under CC BY license. 1. Introduction
Tryptamine is a biogenic amine structurally related to 5-
hydroxytryptamine (5-HT) that is generated in the body by neural
and peripheral tissues. It is also formed by themicroﬂora in the gastro-
intestinal tract and is a component of many food items. Tryptamine is
implicated in various cardiovascular pathologies, including hyperten-
sion, myocardial infarction and migraine. Migraine cluster headaches
have been shown to be relieved by psilocybin, a component of magic
mushrooms, whose active metabolite, psilocin is a trypamine ana-
logue (N,N-dimethyltryptamine). This action is at a subhallucinogenic
dose and likely due to cardiovascular actions (Sewell et al., 2006). The
concentration of tryptamine in serum is correlated with that of its
precursor L-tryptophan (Wollman et al., 1985), which is metabolised
into tryptamine by aromatic L-amino acid decarboxylase. Tryptaminerol; DRC, dose–response curve;
3, inositol 1,4,5-trisphosphate;
methyl ester; NO, nitric oxide;
tor; PIP2, phosphatidylinositol
lipase C; PKC, protein kinase C;
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license. is deaminated by monoamine oxidase (MAO) types A and B (Tipton
et al., 2004) to indole-3-acetaldehyde, which is subsequently reduced
by aldehyde dehydrogenase to indole-3-acetic acid (Weissbach et al.,
1959).
Tryptamine increases blood pressure (Eble, 1965), an effect that
has long been held to be due to indirect sympathomimetic actions,
since it may be regarded as a trace amine (Zucchi et al., 2006). Indi-
rect sympathomimetic amines release noradrenaline from sympathetic
neurones onto vascular α-adrenoceptors to cause vasoconstriction
(Trendelenburg, 1972). However, in isolated vascular tissues, trypt-
amine has been shown to cause vasoconstriction of rabbit aorta
not by an indirect mechanism but by direct stimulation of both
α-adrenoceptors and 5-HT receptors (Stollak and Furchgott, 1983).
Vasoconstriction by tryptamine has also been demonstrated in rat
mesenteric arteries (Watts et al., 1994), rat caudal arteries (Hicks
and Langer, 1983; Bradley et al., 1985) and rat aorta (Fehler et al.,
2010). Hicks and Langer (1983) suggested that speciﬁc tryptaminergic
receptors mediated the vasoconstriction by tryptamine in rat tail
arteries. More recently, the vasoconstriction of rat aorta by trypt-
amine and other trace amines has been shown to be resistant to
blockade by α-adrenoceptor and 5-HT antagonists (Broadley et al.,
2009; Fehler et al., 2010). The vasoconstrictor response was attributed
(Broadley et al., 2009; Broadley, 2010) to the recently described trace
amine-associated receptors (TAARs) (Borowsky et al., 2001; Bunzow
et al., 2001).
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in health and disease, there is a paucity of data on the receptors
activated by this amine and their signalling pathways in vascular
smooth muscle. The few mechanistic studies that do exist have
focussed on the phospholipids. In rat cortical slices, tryptamine-
induced stimulation of inositol phosphate (IP) accumulationwas insen-
sitive to atropine, cyproheptadine, haloperidol, phenoxybenzamine
and propranolol indicating that classical neurotransmitter receptors
were not involved (Osborne et al., 1986). In a later study, tryptamine
activation of primary cultures of rat cerebellar granule cells increased
IP turnover, which was not counteracted by atropine, ketanserin and
prazosin (Ishitani et al., 1994). Subsequently, it was shown that in
NIH3T3 ﬁbroblasts stably expressing the 5-HT2A receptor, tryptamine
activated the phospholipase C (PLC) and phospholipase A2 (PLA2)
signalling pathways (Kurrasch-Orbaugh et al., 2003).
In the rat mesentery, we have recently demonstrated that trypt-
amine mediates both vasopressor and vasodepressor responses.
The vasoconstrictor response was blocked by the 5-HT antagonists,
ritanserin and ketanserin, and is therefore mediated predominantly
via 5-HT2A receptors (Anwar et al., 2012). However, there is a clear
lack of data on the mechanisms of tryptamine-induced changes in
vascular tone, speciﬁcally in the resistance size arteries of the mesen-
tery. Based on the knowledge from our mesenteric arterial network
studies and the above-mentioned cellular and tissue experiments,
we undertook the present investigation to assess the contributions
made by selected contractile transduction pathways in tryptamine-
derived vascular tone. We also determined the possible roles of
co-released vasodepressor transducers in modulating tryptamine-
evoked vasoconstriction.
Preliminary accounts of some of these ﬁndings have been reported
to the British Pharmacological Society (Anwar et al., 2006) and the
European Microcirculation Society (Anwar et al., 2008).
2. Materials and methods
2.1. Animal care
Male Sprague–Dawley rats (250–350 g body weight; Harlan,
Bicester, Oxfordshire, U.K.) were housed in temperature (22±1 °C)
and humidity (50%) controlled quarters on a 12 h light–dark cycle
(07.00–19.00 h light and 19.00–07.00 h dark), 4 animals to a cage,
and provided with food and water ad libitum. They were killed by
cervical dislocation following stunning in accordance with the
Home Ofﬁce Guidance on the operation of The Animals (Scientiﬁc
Procedures) Act 1986 (H.M.S.O.), and after local ethical review by
the Animal Care and Use Committee of Cardiff University.
2.2. Isolated mesenteric arterial bed
The mesenteric vascular bed was exposed through a midline lapa-
rotomy incision; the superior mesenteric artery was cleaned of adi-
pose and connective tissues. The artery was cannulated, close to the
junction with the abdominal aorta, with a PE-50 polyethylene (BD
Intramedic, Oxford, U.K.) cannula, which was ligated and secured
with cotton ties, and the mesenteric vascular bed was immediately
perfused with Krebs'–Henseleit-bicarbonate solution, composition in
mM: NaCl 118.0, KC1 4.7, NaHCO3 25.0, CaCl2 2.5, KH2PO4 1.2, MgSO4
1.2, and glucose 11 (osmolality≅292 mosmol/kg H2O), warmed to
37 °C and gassed continuously with 5% CO2/95% O2 to maintain the
pH at 7.4. The initial ﬂow rate was set at 2 ml perminute using a Gilson
peristaltic pump to remove blood andmetabolites. Simultaneously, the
mesenteric bed was excised by gently separating from the gastroin-
testinal tract (stomach to anterior of rectum), placed in a thermo-
static perfusion chamber, and the arterial network was perfused at
a constant ﬂow rate (4 ml min−1) that was maintained throughout
the experimental procedure (McGregor, 1965). Changes in perfusionpressure, a reﬂection of vascular resistance, were monitored by a
pressure transducer (Elcomatic EM 750, Elcomatic Ltd., Glasgow,
U.K.) located immediately proximal to the inﬂow cannula. The trans-
ducer was coupled to a PowerLab/4SP computerised data acquisition
system (AD Instruments, Charlgrove, Oxon, U.K.) and Chart version 5
software (AD Instruments, U.K.) to display and analyse data. A
bubble trap, distal to the cannulated mesentery and proximal to
the perfusate solution, removed any air bubbles in the perfusate
and also dampened pulses in ﬂow.
2.3. Experimental protocols
After an equilibration period of 1 h, each arterial preparation was
subjected to one of the following experimental protocols. Concentra-
tions of signalling pathway inhibitors were chosen based on previ-
ously published data. Dose–response curves (DRC) to tryptamine by
bolus injection (100 μl volume) were constructed in logarithmic
increments in the absence and repeated in the presence of continuous
infusion of inhibitors in the same preparation. The response of the
preceding dose was permitted to return to the base line before the
start of the next incremental dose. Each inhibitor was infused for
approximately 20 min prior to the commencement of the subsequent
DRC. A 30 min washout interval was allowed between successive
dose–response curves.
2.3.1. Effects of shear stress
Shear stress, the frictional force generated by blood ﬂow acting on
the luminal wall, is known to have a profound effect on the endothe-
lium, and therefore its inﬂuence on vascular reactivity (Davies, 1995).
Consequently, ﬂow–pressure relationships were determined by
incrementally ramping ﬂow rate to achieve a perfusion pressure of
45 mm Hg (Fulep et al., 2002). The ﬂow rate–perfusion pressure rela-
tionship was examined in the absence and presence of L-NAME
(100 μM).
2.3.2. Drug interventions
To elucidate whether the endothelium could modulate tryptamine-
associated vasoconstriction, endothelium denudation was achieved by
perfusing distilled water for 4 min through the mesenteric arterial net-
work, followed by perfusionwith Kreb's solution for 30 min. The extent
of endothelium disruption was conﬁrmed by acetylcholine-induced
(10−7 M) relaxation of pre-constricted vascular bed (10 μM phenyl-
ephrine). Tissues exhibiting inhibition of the acetylcholine-induced
vasodilatation by more than 50% were considered acceptable for inclu-
sion in the study.
To examine the roles of 5-HT2A receptors, nitric oxide (NO), mono-
amine transporters, monoamine oxidases A and B (MAOA/B), phos-
pholipase C (PLC), phospholipase A2 (PLA2), Rho-kinases (ROCK),
cyclooxygenases 1 and 2 (COX1 and COX2), prostanoid receptors (EP1
and TP) and prostacyclin synthase (PGI2 synthase), DRCs for tryptamine
were constructed in the absence and presence of ritanserin (100 pM),
L-NAME (100 μM), cocaine (10 μM), U73122 (synthetic aminosteroid
compound, 10 μM), PACOCF3 (calcium-independent PLA2 antagonist,
10 μM); indomethacin (a non-selective (COX) inhibitor, 10 μM),
nimesulide (selective COX-2 antagonist, 10 μM), tranylcypromine
(a prostacyclin synthase and non-speciﬁc MAOA and MAOB inhibitor,
10 μM), AH 6809 (PGE2 receptor (EP1 and EP2)/less selective PGD2
receptor (DP) antagonist, 10 μM), ICI 192,605 (TP receptor antagonist;
10 μM), and the ROCK inhibitors, Y-27,632 (10 μM) and fasudil (also
known as HA-1077, 20 μM).
2.4. Data and statistical analysis
Responses to each dose of tryptamine were measured as the in-
crease in perfusion pressure from the baseline immediately preceding
the ﬁrst dose. Data are expressed as mean±S.E.M. n indicates the
142 M.A. Anwar et al. / Vascular Pharmacology 58 (2013) 140–149number of animals used. Individual DRCs were plotted as mean in-
crease in perfusion pressure (mm Hg), and the dose–response curves
were ﬁtted to a four parameter logistic model to calculate ED50 values
(the concentration of agonist which produces a response halfway
between the baseline and maximum response, Emax) using FigP
(Biosoft, Cambridge, U.K.). From these quantities, geometric means
of ED50 and Emax with 95% conﬁdence limits were computed.
Linear correlation analysis and signiﬁcances of differences between
control and paired Emax and ED50 values were obtained by paired
Student's t-test. Comparisons of Emax and ED50 values between different
tissues were made by Student's unpaired t-test, and comparisons
between more than two groups were made by ANOVA followed by
Tukey's multiple comparison test. A P value of b0.05 was considered
to be statistically signiﬁcant.2.5. Drugs and chemicals
The following drugs were used and were purchased from Tocris
(Bristol, U.K.): AH-6809, fasudil, 1-[6-[[(17b)-3-methoxyestra-1,3,5(10)-
trie-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione, ICI-192,605 (4-(Z)-6-(2-
o-Chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl)hexenoic acid),
nimesulide, PACOCF3 (palmitoyl triﬂuoromethyl ketone), ritanserin,Ritanserin
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Fig. 1. Dose–response curves for increases in perfusion pressure by tryptamine of rat isolated
boluses (nmoles/100 μl). Each response is the mean±S.E.M. increase in perfusion pressure. A
and repeated in the presence (■, n=3) of ritanserin (100 pM). * Signiﬁcantly different from
endothelium (□, n=4) and in de-endothelialised (■, n=4) mesenteric arterial bed. * Sig
absence (□) and presence (■, n=7) of L-NAME (100 μM). All points signiﬁcantly different
presence of ritanserin (◆, 100 pM) and in the additional presence (▲, n=3) of L-NAME (10U73122 and Y-27,632. The following drugs were acquired from
Sigma-Aldrich (Poole, UK): acetylcholine, cocaine hydrochloride, 5-
hydroxytryptamine (5-HT) hydrochloride, indomethacin [1-(4-
chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid], L-NAME
(Nω-nitro-L-arginine methyl ester), pargyline, tranylcypromine (trans-
2-phenyl-cyclopropylamine hydrochloride), tryptamine hydrochloride,
U-46619 (9,11-dideoxy-9a, 11a-methanoepoxy prostaglandin F2a).
All agonists and inhibitors were prepared in distilled water, except
indomethacin, U73122, ICI 192,605, ritanserin and PACOCF3 which
were dissolved in ethanol and AH6809 which was dissolved in
1.1 eq of NaOH. The stock solutions were stored frozen in aliquots,
and when required were thawed and diluted. All drug dilutions
were made using Krebs' solution. To eliminate any possible effect of
the vehicle on vascular reactivity, the concentration of ethanol used
when required was ≤0.1% (vol/vol) in the perfusion ﬂuid (Moreau
et al., 1997).3. Results
Basal perfusion pressure was 21.2±0.5 mm Hg for n=75 ani-
mals; unless otherwise indicated, there was no effect of inhibitors
on basal perfusion pressure.Endothelium removal
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perfused mesenteric arterial bed. Doses of tryptamine were administered as individual
. Dose–response curves for vasoconstrictor responses to tryptamine in the absence (□)
the absence of ritanserin, Pb0.05. B. Dose–response curves for tryptamine with intact
niﬁcantly different from intact endothelium, Pb0.05. C. Dose–response curves in the
between tryptamine alone and with L-NAME, Pb0.05. D. Dose–response curves in the
0 μM). * Signiﬁcantly greater than ritanserin alone, Pb0.05, ** Pb0.01.
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Tryptamine caused dose-related increases in perfusion pressure.
These responses were inhibited in the presence of ritanserin (100 pM)
(Fig. 1A).3.2. De-endothelialization and inhibition of nitric oxide synthase (NOS)
On denudation of the mesenteric arteries, the basal perfusion
pressure was signiﬁcantly increased (13±1 vs 18±1 mm Hg,
Pb0.01). Moreover, the removal of endothelium augmented the max-
imum contractile response to tryptamine (Fig. 1B). In the presence
of L-NAME (100 μM) the constrictor responses to tryptamine were
potentiated (Fig. 1C) and the maximum response was signiﬁcantly
greater than in the control mesenteries (Table 1). When L-NAME
was introduced in the presence of ritanserin (100 pM), small vaso-
constrictor responses to tryptamine were reinstated (Fig. 1D).Table 1
Potency and maximum vasoconstrictor responses for tryptamine in the absence and
presence of inhibitors in the rat isolated perfused mesenteric arterial beds.
Signalling pathway
and inhibitor
Potency
(ED50, nmol/100 μl)
Maximum effects
(Emax, mm Hg)
n
5-HT2A receptors
Control 32.0 (22.4–45.6) 37.3±3.3 9
Ritanserin (100 pM) 103.9 (14.2–760) 2.0±0.4$$ 3
Nitric oxide synthase
Control 35.2 (25.9–47.8) 32±3 7
L-NAME (100 μM) 33.4 (17.4–64.2) 90.1±10.3⁎⁎⁎ 7
L-NAME+ritanserin 9.0 (1.3–61.0) 8.6±1.2 3
Denudation
+ Endothelium 81.0 (63.3–103.5) 12.4±1.5 4
− Endothelium 96.8 (24.7–379.2) 20.0±2.3⁎ 4
Monoamine transporter
Control 46.9 (33.7–65.4) 27±1 4
Cocaine (10−5 M) 46.4 (33.2–64. 7) 51±3⁎⁎ 4
Cocaine+L-NAME 22.1 (6.5–75.5)## 126.4±6.9### 4
Phospholipase C
Control 38.8 (24.1–62.5) 43±6 4
U73,122 (10−5 M) ND 8.6±1.7⁎⁎ 4
Phospholipase A2
Control 29.6 (12.8–68.4) 18±2 3
PACOCF3 (10−5 M) 92.1 (55.5–152.8)⁎ 18±2 3
Rho-kinase
Control 26.2 (12.5–54.7) 20±4 3
Y-27,632 (10−5 M) 18.9 (5.9–61.0) 11±3⁎⁎ 3
Control 27.50 (13.24–57.1) 26±3 3
Fasudil (2×10−5 M) 18.9 (4.3–82.6) 9±1⁎⁎ 3
COX-1 and COX-2
Control 29.2 (17.0–50.1) 25±3 5
Indomethacin (10−5 M) ND 10.4±1.7⁎⁎ 5
COX-2
Control 28.9 (12.7–65.7) 45±1 3
Nimesulide (10−5 M) 57.6 (52.7–63.0)⁎ 22±2⁎⁎ 3
Prostanoid EP1 receptor
Control 32.0 (21.1–48.7) 20±3 4
AH-6809 (10−5 M) 49.0 (32.6–73.7)* 14±3 4
Prostacyclin synthase/MAO
Control 29.4 (21.2–40.8) 28±7 5
Tranylcypromine (10−5 M) 20.1 (14.1–28.6)⁎ 27±3 5
Thromboxane TP receptor
Control 29.8 (20.5–43.4) 24±5 4
ICI 192605 (10−6 M) 28.8 (15.6–53.5) 27±5 4
Potency is represented as the geometric mean (with 95% conﬁdence intervals) ED50
(nmole/100 μl) and the maximum response is displayed as arithmetic mean±S.E.M
maximum increase in perfusion pressure (mm Hg). n is the number of animals. * Repre-
sents signiﬁcant differences from paired control values by Student's paired t-test,
Pb0.05, ** Pb0.01 and *** Pb0.001. $$ Signiﬁcant difference from unpaired controls by
Student's unpaired t-test, Pb0.01. ## Signiﬁcant differences between the L-NAME plus
cocaine group and control or cocaine alone by one-way ANOVA with Tukey's multiple
comparison test, Pb0.003, ### Pb0.0001. ND, not determined.To examine the role of shear stress on the perfusion pressure and
whether nitric oxide was released by the increasing shear stress dur-
ing vasoconstrictor responses, the relationship between ﬂow rate and
perfusion pressure was examined. Increasing ﬂow rate resulted in a
linear increase in perfusion pressure (Fig. 2). This ﬂow rate–perfusion
pressure relationship was identical in the presence of L-NAME
(100 μM) (Fig. 2).
3.3. Phospholipase and cyclo-oxygenase pathways
The non-selective phospholipase C inhibitor, U73122 (1 μM),
abolished the tryptamine-induced vasoconstrictor responses of the
mesenteric arteries (Fig. 3A and Table 1), and it was not possible to
ascertain an ED50 value. The competitive phospholipase A2 (iPLA2)
inhibitor, PACOCF3, also antagonised the responses to tryptamine as
a shift of the DRC to the right (Fig. 3B), reﬂected by the reduced
potency (Table 1). Indomethacin (a non-speciﬁc COX inhibitor) almost
completely abolished the vasoconstrictor responses to tryptamine
(Fig. 3C), precluding determination of an ED50 value. Nimesulide, a spe-
ciﬁc COX-2 inhibitor, signiﬁcantly attenuated the maximum response
from 45±1 to 22±2 mm Hg (Fig. 3D).
3.4. Prostanoid receptors
The EP1 prostanoid receptor inhibitor, AH6809 (10 μM), shifted
the DRC for tryptamine to the right and signiﬁcantly increased the
ED50 value (Fig. 4A). Tranylcypromine (a prostacyclin synthase inhib-
itor and non-selective MAO-A and MAO-B inhibitor) increased the
sensitivity to tryptamine only at the lower concentrations (Fig. 4B).
The potency and maximum responses of the mesenteric arterial bed
to tryptamine were unaltered in the presence of the thromboxane
TP receptor antagonist ICI 192,605 (Fig. 4C).
3.5. Rho-kinase inhibitors
The tryptamine-dependent vasoconstriction was inhibited by the
Rho/Rho-kinase inhibitors. The maximum response to tryptamine
was signiﬁcantly inhibited to 45% by Y-27632 (Fig. 5A) and to 65%
by fasudil (Fig. 5B).
3.6. Monoamine transporter
The presence of the neuronal amine transport inhibitor, cocaine
(10 μM), signiﬁcantly enhanced the tryptamine vasoconstrictor re-
sponses without altering the sensitivity (Fig. 6A and Table 1). Whenpressure-flow relationship
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Fig. 3. Effects of phospholipase and COX inhibitors on dose–response curves for tryptamine-induced vasoconstriction of rat isolated perfused mesentery. Dose–response curves in
the absence (□) and presence (■) of A. phospholipase C inhibitor, U73,122 (10 μM, n=4), B. phospholipase A2 inhibitor, PACOCF3 (10 μM, n=3), C. COX-1/COX-2 inhibitor, indo-
methacin (10 μM, n=5), and D. COX-2 inhibitor, nimesulide (10 μM, n=3). * Signiﬁcantly different points from tryptamine alone, Pb0.05, ** Pb0.01. Each response is the mean±
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an additional potentiation, the maximum vasoconstriction reaching
126.4±6.9 mm Hg, which was signiﬁcantly greater than with L-NAME
alone (90.1±10.3 mm Hg).
4. Discussion
This study has conﬁrmed previous reports that tryptamine exerts
vasoconstrictor properties in the rat isolated mesenteric arteries
(Watts et al., 1994) and in the rat isolated perfused mesenteric arte-
rial bed (Anwar et al., 2012). Tryptamine also causes vasoconstriction
in rat (Fehler et al., 2010) and rabbit (Stollak and Furchgott, 1983)
aorta and rat caudal arteries (Hicks and Langer, 1983; Bradley et al.,
1985). This response would explain the increases in blood pressure
observed when trypamine is administered to dogs (Eble, 1965). The
tryptamine induced pressor response of the mesenteric bed was
inhibited by the 5-HT2A receptor antagonist, ritanserin, indicating
that the vasoconstriction is largely via activation of 5-HT2A receptors.
This is at variance with the vasoconstriction in other vessels such as
the rat aorta where the vasoconstriction by tryptamine is not
inhibited by another 5-HT2A receptor antagonist, ketanserin (Fehler
et al., 2010), although in the rabbit aorta (Stollak and Furchgott,
1983) and rat tail artery (Bradley et al., 1985), 5-HT antagonists
were effective. The main aim of this study was to determine the sig-
nalling pathways for this 5-HT2A-mediated vasoconstriction by trypt-
amine by the use of appropriate inhibitors. Secondly, we examined
whether the response was modulated through co-activation of relax-
ant signalling mechanisms.4.1. Contractile transducers
4.1.1. Phospholipid signalling cascades
Activation of G protein-coupled receptors, such as 5-HT2A receptors,
stimulates phospholipase C, the catalysed products of which funnel
out to further amplify downstream signalling transducers of smooth
muscle contractile responses. Stimulation of phospholipase C catalyses
the hydrolysis of the phosphorylated lipid, phosphatidylinositol 4,
5-bisphosphate (PIP2) to produce second messengers, inositol 1, 4,
5-trisphosphate (IP3) and diacylglycerol (DAG), (Rhee, 2001, Fig. 7).
IP3 through the activation of IP3 receptors (IP3Rs), located on store-
operated calcium channels, mobilises calcium into the cytosol from
intracellular stores (sarcoplasmic/endoplasmic reticulum, Golgi com-
plex and the nuclear envelope), leading to contraction (Berridge,
1993). Tryptamine activates heterotrimeric G protein-coupled 5-HT2A
receptors, which are linked to the PLC signalling system since the con-
tractile response was completely eliminated by U73122, a putative
blocker of PLC (Osol et al., 1993). DAG, the other transducer arising
from PLC activation, stimulates protein kinase C (PKC), (Nishizuka,
1995). DAG activation of PKC is the initial step in the prostaglandin bio-
synthetic pathway initiated by activation of a family of phospholipase A2
(PLA2) isozymes [secretory PLA2s (sPLA2), the cytosolic PLA2s (cPLA2),
calcium-independent PLA2s (iPLA2) and the platelet activating factor
(PAF) acid hydrolases]. These are primarily responsible for agonist-
induced hydrolysis of the sn-2 ester bonds in membrane phospholipids,
such as phosphotidyl choline and phosphotidylethanolamines, releasing
arachidonic acid and lysophospholipids (Schaloske and Dennis, 2006;
Fig. 7).
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145M.A. Anwar et al. / Vascular Pharmacology 58 (2013) 140–149The present investigation has shown that a Ca2+-independent PLA2
is involved in tryptamine-induced vasoconstriction, since the response
was signiﬁcantly attenuated by the iPLA2 inhibitor, PACOCF3. Previous
studies have conﬁrmed the iPLA2 blocking activity of PACOCF3
(Ackerman et al., 1995) and demonstrated the PKC-dependent pro-
moting activity of calcium-independent phospholipase A2 β (iPLA2β,
group VIB PLA2) and liberation of arachidonic acid (Jenkins et al.,
2002; Akiba and Sato, 2004). Moreover, diacylglycerol has been
shown to be a substrate for DAG lipase, which leads to the synthesis
of 2-arachidonylglycerol, which is metabolised by monoacylglycerol
lipase or fatty acid amidohydrolase to also yield arachidonic acid
(Tang et al., 2006).Interestingly, our results differ from the 5-HT2A receptor-mediated
PLC and PLA2 signalling pathways in NIH3T3–5HT2A ﬁbroblast cells,
which are independently coupled to the receptor (Kurrasch-Orbaugh
et al., 2003). This is perhaps due to a. overexpression of the receptor
in NIH3T3 ﬁbroblasts, b. the different cell types involved, or c. the static
milieu of cell culture as opposed to the dynamic environment of the
perfused isolated vascular bed.
4.1.2. Cyclooxygenases
Conversion of arachidonic acid to PGG2 is via a cyclooxygenase
reaction, which is followed by a peroxidase reaction to PGH2, these
are the committed steps in prostanoid biosynthesis, and both are
mediated by two prostaglandin synthases or cyclooxygenases (COX-1
and COX-2) (Simmons et al., 2004).
Cyclooxygenases play a pivotal role in prostaglandin and/or
thromboxane synthesis and their consequent vasoconstrictor effects
(Simmons et al., 2004). The present study implicates both COX
isoforms as constitutive enzymes in mediating vasoconstriction of
the mesenteric arteries by tryptamine. The non-selective COX inhibi-
tor, indomethacin, virtually abolished the vasoconstrictor responses
to tryptamine whereas the COX-2-selective inhibitor, nimesulide,
only halved the maximum response. This leads to the conclusion that
both isoforms are involved in the vasoconstrictor response. Previous re-
ports of expression of the two COX isozymes in different tissues,
including the vasculature, from human and animal studies are in
accord with our results (Ermert et al., 1998; Wang et al., 2005; Ho and
Randall, 2007; Trappe et al., 2008). It is important to note that the
abolition of the vasopressor responses by indomethacin indicates that
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are not involved in the tryptamine-mediated vasoconstriction.
4.1.3. Prostanoids
The PGH2 derived from cyclooxygenase activation is subsequently
converted to a variety of bioactive prostanoids, such as thromboxane
(TxA2) and prostaglandins F2α, D2, E2 and I2 (prostacyclin), depending
on the downstream enzymatic machinery present in a particular cell
type (Coleman et al., 1994; Breyer et al., 2001). Prostaglandin PGE2
has been implicated in a plethora of physiological processes in vascu-
lar smooth muscle and endothelial cells, including vascular tone, cel-
lular signalling, proliferation, migration and tubulogenesis (Sugimoto
and Narumiya, 2007). PGE2 exerts the majority of these pleiotropic
actions in diverse tissues through a family of four G protein-coupled
heptahelical cell surface receptors (EP1 to EP4), (Narumiya et al.,
1999). The EP1 receptor antagonist, AH-6809, signiﬁcantly inhibited
the tryptamine-induced vasoconstriction, illustrating that PGE2 is
probably the main prostanoid generated which induces tryptamine
vasoconstriction in the mesenteric arterial bed via EP1 receptors.
Stimulation of the EP1 receptor, through a Gq protein, activates PLC/
inositol triphosphate and protein kinase C (PKC) signalling and is
coupled to intracellular Ca2+ elevation (Boie et al., 1997), resulting
in vasoconstriction (Fig. 7). In support of a role for EP1 receptors in
mediating vasoconstrictor responses, PGE2- and 17-phenyl-trinor-
PGE2 (selective EP1 receptor agonist)-induced vasoconstriction in
isolated pressurised gracilis muscle arterioles of db/db mice was
attenuated by pre-treatment with AH6809 (Rutkai et al., 2009). We
next examined whether thromboxanes and thromboxane receptors
(TP) were involved in the vasoconstrictor response. The thromboxanereceptor inhibitor ICI 192,605 had no effect on the vasoconstrictor
responses to tryptamine. Previous studies have shown that vaso-
constriction of rat mesenteric arteries by PGE2 was unaffected by
the thromboxane A2 (TxA2) receptor blocker SQ 29,548, whereas
the response to PGF2α was abolished. The thromboxane A2 mimetic,
U-46619, also contracted the rat mesenteric resistance arteries but
was inhibited by an EP1 receptor antagonist (SC-19220) and attribut-
ed to release of PGE2 by U-46619 into the mesenteric perfusate (Bolla
et al., 2004). A link can therefore be established in the vasoconstrictor
response to tryptamine between activation of phospholipases C and
A2, liberation of arachidonic acid and generation of the vasocon-
strictor prostaglandin E2 via cyclooxygenase. A similar link has been
shown in cultures of A-10 vascular smooth muscle cells isolated
from wild-type mice, where iPLA2β catalysed the liberation of ara-
chidonic acid which binds to COX-2 to produce PGE2. In contrast,
the concentration of PGE2 was dramatically reduced in media
obtained from iPLA2β-null mice VSMC cultures (Moon et al., 2008).
Thus, tryptamine-induced contraction appears to be mediated via
the prostanoid PGE2 through EP1 receptors, but there is no participa-
tion of thromboxanes or receptors for TxA2.
4.1.4. Rho-kinases
Heterotrimeric G-proteins of the Gα12 and Gα13 family transduce
signals emanating from GPCRs to activate the low molecular weight
guanosine triphosphate (GTP)-binding protein RhoA, a member of
the Ras family of proteins, and its downstream target, Rho-kinase (a
p160 Rho-associated coiled-coil-containing protein kinase, a serine/
threonine speciﬁc kinase). Rho-kinase has 2 isoforms: ROKα/ROCKII
and ROKβ/ROCKI, which are important regulators of vascular tone
(Somlyo and Somlyo, 2003). During this calcium-independent pro-
cess, Rho-kinase causes inhibition of myosin light chain phosphatase
activity by phosphorylation of its myosin-binding subunit (a regula-
tory domain), resulting in elevated vascular tension. This phenome-
non is referred to as calcium sensitisation (Uehata et al., 1997).
We have demonstrated that the 5-HT2A receptors stimulated
by tryptamine are coupled to the Rho/ROCK signalling pathway by
way of attenuation of the vasoconstrictor response to tryptamine by
fasudil (active component: hydroxyfasudil) and Y-27632. Fasudil
and Y-27632 block the activity of Rho-kinase by competing with the
ATP-binding site on the enzyme (Jacobs et al., 2006).
4.2. Dilator mediators
4.2.1. Nitric oxide
Inhibition of NO release with the nitric oxide synthase inhibitor,
L-NAME, caused almost three-fold increase in the maximum vaso-
constriction of the rat mesentery by tryptamine. Similarly, endo-
thelium denudation potentiated the maximum response. The
heterotrimeric G protein Gα12 is coupled to eNOS leading to elevated
intracellular concentrations of eNOS (Andreeva et al., 2006). The
effects of NO are mediated primarily through the direct activation
of soluble guanylate cyclase, generating cyclic guanosine mono-
phosphate (cGMP) (Andreopoulos and Papapetropoulos, 2000;
Lucas et al., 2000), which stimulates protein kinase G (PKG, also
termed cGMP-targeted kinase, cGK), which can suppress Gαq stimu-
lation by interaction with regulator of G-protein coupled signalling
2 (RGS2) (Hofmann et al., 2000). To note, vasodilation of mice aortic
rings by PGE2 interaction with the EP4 receptor results in NO forma-
tion (Hristovska et al., 2007). The high bioavailability of NO counter-
acts the contractile actions of COX-metabolites (Miyamoto et al.,
2007) and Rho-kinase (Sauzeau et al., 2000). Consequently, NO serves
as a homeostatic buffer against incremental or excessive vasocon-
striction and smoothes out excessive ﬂuctuations in blood pressure.
When NO was inhibited by L-NAME after blockade of the trypt-
amine vasoconstriction by the 5-HT2A antagonist, ritanserin, small
vasoconstrictor responses were restored. These cannot be due to
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the doses of tryptamine are unchanged. Our previous study showed
that in the presence of 5-HT2A receptor blockade and with perfusion
pressure raised by perfusion with phenylephrine, tryptamine causes
dose-related vasodilatation which is NO-mediated (Anwar et al.,
2012). When this vasodilator action is removed by L-NAME, a vaso-
constriction appears. This was not examined further but may be due
to activation of trace amine-associated receptors, which appear to
mediate vasoconstrictor responses to tryptamine and other trace
amines in other blood vessels such as coronary arteries (Herbert
et al., 2008) and rat aorta (Fehler et al., 2010).
4.2.2. Shear stress
According to the Hagen–Poiseuille equation, vascular resistance is
a function of vascular geometry (radius and length of vessel) and
viscosity of ﬂuid (η). The resistance of a blood vessel is related to
the inverse of the fourth power of vessel diameter and therefore
small reductions in diameter have signiﬁcant consequences for vascu-
lar resistance. Graded increases in ﬂow rate through the rat mesen-
teric bed induced by raising the pump ﬂow rate were associated
with corresponding rises in perfusion pressure. This is a reﬂection of
an increase in vascular smooth muscle tone due to elevations in
wall shear stresses, which leads to an increase in vascular resistance.
The possibility was considered that these increases in shear stress
might cause release of vasodilator NO which could dampen the pres-
sure increases. However, inhibition of NO synthesis with L-NAME had
no inﬂuence on ﬂow rate–perfusion pressure relationship. Our results
are consistent with the ﬁndings of unchanged perfusion pressureafter incubation with L-NAME in the non-pregnant rat isolated uter-
ine bed (Fulep et al., 2002) and non-pregnant rat isolated perfused
mesenteric arteries (Cockell and Poston, 1996). However, they con-
trast with ﬂow experiments on cultured endothelial cells (Kuchan
and Frangos, 1994), where NO was found to be released. Therefore,
in our study NO release can be attributed to tryptamine stimulation of
post-receptor pathways and not as a result of any shear forces exerted
on the luminal wall by the vasoconstriction. The possibility, however,
arises that increasing perfusion pressure by pump-mediated increases
in ﬂow does not entirely mimic the increase due to vasoconstriction.
The possibility must be considered that a part of the NO release by
tryptamine results from conformational changes of endothelial cells
arising from vasoconstriction. The effects of L-NAME on a wider range
of vasoconstrictor agents acting via different receptors would be
required to test this idea further.
It is worth mentioning that links have been established between
nitric oxide and the Rho-kinase signal transduction pathways. NO
can cause vasodilatation through inhibition of the RhoA/Rho-kinase
(ROCK) signalling pathway in vascular smooth muscle (Sauzeau et al.,
2000), rat coelic artery (Teixeira et al., 2005) and rat aorta (Chitaley
and Webb, 2002). On the other hand, the RhoA/Rho-kinase pathway
prevents protein kinase B/Akt-dependent eNOS activity in human
endothelial cells (Ming et al., 2002). A more recent study has provided
evidence that Rho-kinase signalling activity was ampliﬁed in endo-
thelial nitric oxide synthase (eNOS) nullmice (Williams et al., 2006). Fur-
ther complexity arises from results suggesting that arachidonic acid
generated by phospholipids can activate ROCK (Araki et al., 2001; Guo
et al., 2003), and perhaps contribute to Ca2+-sensitization by tryptamine.
148 M.A. Anwar et al. / Vascular Pharmacology 58 (2013) 140–1494.2.3. Prostacyclin
Prostacyclin (PGI2) is a vasodilator prostanoid produced by endo-
thelial cells as a key mediator in the regulation of vascular tone and
blood pressure. Thus potentiation of the tryptamine-elicited vasocon-
striction by endothelial cell denudation can be partly explained by re-
moval of prostacyclin as well as removal of vasodilator nitric oxide.
PGI2 exerts its cellular effects by binding to a G protein-coupled re-
ceptor, IP. Stimulation of the IP receptor, coupled to Gs-type G protein,
activates adenylate cyclase leading to cAMP formation, and therefore
to vasodilatation of the mesenteric vessels (Hata and Breyer, 2004).
We examined whether tryptamine would release prostacyclin by
use of a potent prostacyclin synthase antagonist, tranylcypromine
(Xavier et al., 2008). The vasoconstrictor response was augmented
at the lower doses of tryptamine, suggesting that at lower concen-
trations prostacyclin was indeed released by tryptamine. However,
tranylcypromine is also a non-selective inhibitor of monoamine
oxidases (MAO) A and B (Blackwell, 1963). MAO A and B activities
appear to be associated with the mesenteric arteries of various species
(Coquil et al., 1973; Caramona, 1982). Thus, an alternative explanation
for the enhanced responses at lower doses is that tryptamine is
metabolised by MAO in the mesenteric bed and its inhibition by
tranylcypromine allows elevated levels to reach the receptors.4.3. Monoamine transporters
Cocaine is a nonselective, competitive inhibitor of monoamine
reuptake, inhibiting the dopamine (DAT), noradrenaline (NAT) and
5-HT (serotonin, SERT) transporters with Ki values of 267 nM,
872 nM and 392 nM, respectively (Torres et al., 2003). Therefore,
cocaine is over 2-fold more potent at the serotonin than the nor-
adrenaline transporter. Tryptamine is a substrate for the serotonin
transporter (Segonzac et al., 1985; Adkins et al., 2001) and mesen-
teric arteries are known to express the SERT (Ni et al., 2004). Thus,
inhibition of the transporter would be expected to increase the trypt-
amine concentration in mesenteric circulation. Indeed, cocaine mod-
erately potentiated the contractile response of mesenteric arteries
to tryptamine. When cocaine was combined with L-NAME, there
was an additional potentiation which we assume is due to the com-
bined additive effects of inhibition of tryptamine transport and re-
moval of the opposing vasodilator effects of released NO. There is
one recent report of regulation of nitric oxide enhancing the activity
of the noradrenaline transporter to control blood pressure responses
to tyramine in anaesthetized rats (Simaan and Sabra, 2011). How-
ever, this does not appear to apply to tryptamine responses here,
as L-NAME would have opposed the action of cocaine rather than
enhancing it.4.4. Summary
In summary, tryptamine causes vasoconstriction of rat mesenteric
arterial beds which is mediated via 5-HT2A receptors. This response is
due to a coupling between the tryptaminergic receptors, phospholi-
pases C and A2 and contractile prostaglandins (PGE2). Signalling
through the RhoA/ROCK pathway is also implicated. There is a simul-
taneous release of vasodilator nitric oxide and possibly prostacyclin
from the endothelium which oppose and homeostatically balance
the increases in pressure. Thus, circulating levels of tryptamine
derived from endogenous synthesis or from dietary intake can exert
a regulatory control of mesenteric blood ﬂow and thus the digestive
and absorptive activities of the gastrointestinal tract.Conﬂict of interest disclosure
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